Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTango Therapeutics Inc

Tango Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
22.51 USD 1.01 ( 4.70%)
Last update at 2026-11-09T15:42:00Z
VOLUME
378946
Market Cap
731.90M

Momentum Score

…

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
21.12
Low
22.62
High
52 Week Price Range
2.56
Low
13.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tango Therapeutics is a clinical-stage biotechnology company using functional genomics and synthetic lethality to discover and develop targeted cancer therapies, with a pipeline spanning discovery and clinical programs. Long-term growth may be driven by clinical progress, biomarker-directed patient selection, and leveraging its discovery platform to expand programs or secure collaborations. The precision-oncology focus and a platform-based approach may attract investors seeking exposure to novel cancer mechanisms.
Key risks include high clinical and regulatory uncertainty, substantial financing needs before potential commercialization, and intense competition in oncology that could limit market opportunities.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
21.50
Dividend Yield
-
Revenue TTM
37.23M
Revenue Per Share
0.37
Gross Profit TTM
-81.05M
Debt / Equity
0.15
ROE
-45.41%
Net Debt
-27.46M
ROCE
-31.60%
Diluted EPS TTM
-1.10

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -108.12M -57.94M -51.97M -
Net income -108.18M -58.23M -51.86M -
Selling general administrative 30.02M 17.60M 9.87M -
Gross profit 24.86M 37.04M 7.66M -
Reconciled depreciation 1.61M 0.90M 0.72M -
Ebit -112.68M -59.09M -52.20M -15.16M
Ebitda -111.07M -58.19M -51.48M -
Depreciation and amortization 1.61M 0.90M 0.72M -
Non operating income net other -1.45M -1.03M - -
Operating income -111.07M -58.19M -52.20M -
Other operating expenses 135.93M 95.23M 59.86M -
Interest expense 2.95M 1.14M 0.00M 0.00M
Tax provision 0.05M 0.29M 0.00M -
Interest income 1.46M 0.49M 0.11M -
Net interest income 1.46M 0.49M 0.11M -
Income tax expense 0.05M 0.29M -0.11M -
Total revenue 24.86M 37.04M 7.66M -
Total operating expenses 135.93M 95.23M 59.86M -
Total other income expense net 2.95M 0.25M 0.23M -
Net income from continuing ops -108.18M -58.23M -51.97M -
Net income applicable to common shares -108.18M -58.23M -51.97M -14.10M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 402.57M 436.47M 500.15M 207.25M -
Other current assets 8.80M 6.57M 4.52M 1.31M -
Total liab 149.46M 186.99M 155.41M 168.65M -
Total stockholder equity 253.11M 249.48M 344.75M 38.60M -
Other current liab 15.40M 17.53M 9.94M 6.14M 19.93M
Common stock 0.10M 0.09M 0.09M 0.04M 0.01M
Capital stock 0.10M 0.09M 0.09M 0.04M -
Retained earnings -371.26M -269.51M -161.34M -103.10M -51.13M
Other liab - - 114.72M 120.81M 14.12M
Other assets - - 1.73M 166.82M 2.28M
Cash 66.39M 59.97M 142.75M 28.38M -
Total current liabilities 45.94M 55.55M 40.69M 40.92M 25.85M
Current deferred revenue 25.67M 31.79M 26.02M 31.98M -
Net debt -27.46M -18.84M -141.24M -20.50M -
Short term debt 2.08M 1.77M 1.50M 0.96M -
Short long term debt total 38.92M 41.13M 1.50M 7.88M -
Other stockholder equity 624.08M 522.61M 506.76M 141.64M 0.01M
Property plant equipment - 10.88M 6.09M 11.30M 11.83M
Total current assets 346.54M 375.27M 492.34M 193.63M 41.66M
Net tangible assets - 249.48M 344.75M -97.94M -47.80M
Short term investments 270.50M 306.17M 342.51M 161.94M -
Net receivables 0.00M 2.00M 2.00M 2.00M -
Inventory - 0.57M 0.57M - -
Accounts payable 2.79M 4.45M 3.23M 1.84M 0.67M
Accumulated other comprehensive income 0.19M -3.71M -0.77M 0.02M -
Common stock total equity - 0.09M 0.09M 157.36M -
Retained earnings total equity - -269.51M -161.34M - -
Non currrent assets other 2.61M 3.43M 1.73M 2.32M -
Non current assets total 56.03M 61.20M 7.82M 13.62M -
Capital lease obligations 38.92M 41.13M 1.50M 7.88M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 34.09M -181.60M -144.32M 2.67M
Change to liabilities -8.13M -10.81M 120.25M -15.22M
Total cashflows from investing activities 26.40M -183.43M -145.47M 0.85M
Total cash from financing activities 1.61M 357.32M 80.88M 11.00M
Change to operating activities - -0.54M 0.42M 1.70M
Net income -108.18M -58.23M -51.97M -14.10M
Change in cash -81.07M 114.36M 5.49M -12.96M
Begin period cash flow 145.02M 30.66M 25.17M -
End period cash flow 63.96M 145.02M 30.66M 25.17M
Total cash from operating activities -109.08M -59.53M 70.07M -24.80M
Issuance of capital stock 0.00M 29.99M 80.84M -
Depreciation 1.61M 0.90M 0.72M 0.64M
Other cashflows from investing activities - - -0.04M -0.04M
Change to inventory - - 0.42M -
Change to account receivables - 0.00M -2.00M -2.00M
Sale purchase of stock - 31.05M - -
Other cashflows from financing activities -0.01M 327.33M -145.47M 326.28M
Change to netincome 13.56M 9.16M 2.65M 2.18M
Capital expenditures 7.69M 1.84M 1.11M 1.82M
Cash flows other operating -7.94M -3.29M - -
Cash and cash equivalents changes -81.07M 114.36M - -
Change in working capital -18.49M -11.35M 118.67M -
Stock based compensation 14.23M 7.83M 1.76M -
Other non cash items 1.75M 1.32M 0.89M -
Free cash flow -116.77M -61.36M 68.97M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TNGX
Tango Therapeutics Inc		 1.01
4.70%		 22.51 - - 21.50 3.10 13.35 -4.36
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Tango Therapeutics Inc

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

201 Brookline Avenue, Boston, MA, United States, 02215

857 320 4900

https://www.tangotx.com

140

Name Title Year Born
Dr. Barbara L. Weber M.D. Pres, CEO & Director 1956
Ms. Daniella Beckman CPA Chief Financial Officer 1979
Dr. Alan Huang Ph.D. Chief Scientific Officer 1973
Dr. Alan Ashworth FRS, Ph.D. Founder & Member of Scientific Advisory Board 1961
Dr. Levi Garraway M.D., Ph.D. Founder NA
Dr. William G. Kaelin Jr., M.D. Founder & Member of Scientific Advisory Board 1958
Dr. Timothy K. Lu M.D., Ph.D. Founder 1981
Dr. Antoni Ribas M.D., Ph.D. Founder & Member of Scientific Advisory Board 1967
Mr. Douglas J. Barry Esq., J.D. Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1970
Mr. John C. Ross M.S. VP of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…